Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NELARABINE vs CLOLAR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Nelarabine is a prodrug of ara-G, a deoxyguanosine analog. It is converted to ara-GTP, which accumulates in T-cells and inhibits DNA synthesis, leading to cell death.
Clolar (clofarabine) is a purine nucleoside antimetabolite that inhibits DNA synthesis and RNA transcription. It is phosphorylated intracellularly to its active triphosphate form, which competes with adenosine triphosphate for incorporation into DNA, leading to chain termination and inhibition of DNA polymerase and ribonucleotide reductase, resulting in apoptosis.
T-cell acute lymphoblastic leukemia (T-ALL),T-cell lymphoblastic lymphoma (T-LBL),Relapsed or refractory T-ALL/T-LBL
FDA: Treatment of relapsed or refractory acute lymphoblastic leukemia (ALL) in pediatric patients aged 1 to 21 years.,Off-label: Treatment of acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), chronic myeloid leukemia (CML) in blast crisis.
1500 mg/m2 intravenously over 2 hours on days 1, 3, and 5, repeated every 28 days.
5 mg/m2 intravenously over 2 hours daily for 5 consecutive days. Repeat every 28 days.
Terminal t1/2: 30 hours (range 21-48 h) in adults; prolonged in renal impairment. Ara-G (active metabolite) t1/2: 3 hours.
Terminal elimination half-life approximately 5.2 hours in patients with normal renal function; prolonged in renal impairment (up to 9.8 hours with Cr Cl <60 m L/min) and in elderly; clinical context: supports once-daily dosing adjustment for renal function.
Nelarabine is demethylated by adenosine deaminase (ADA) to ara-G, which is then phosphorylated to ara-GTP intracellularly. It is partially metabolized by aldehyde oxidase.
Clofarabine is partially metabolized by deamination via cytidine deaminase (CDA) to inactive 6-keto-clofarabine. Approximately 50-60% of the drug is excreted unchanged in urine.
Renal: 50-60% as unchanged ara-G; fecal: <5% as metabolites; biliary: negligible.
Renal: 50-60% as unchanged drug; biliary/fecal: minimal (<5%)
<25% bound to plasma proteins (albumin).
47% bound to human plasma proteins, primarily albumin.
Vd: 197 L/m² (approx 5.6 L/kg based on 1.73 m²/70 kg), indicating extensive tissue distribution.
Central Vd approximately 172 L/m² (extensive tissue distribution); in L/kg: ~4.6 L/kg (assuming 70 kg patient with BSA 1.73 m²). Clinical meaning: indicates wide distribution into total body water and tissues, exceeding total body water.
IV only; oral bioavailability not established (<5% due to extensive first-pass metabolism).
Intravenous: 100% (only route of administration); oral: not available (no oral formulation).
Cr Cl 30-60 m L/min: reduce dose to 975 mg/m2. Cr Cl <30 m L/min: not recommended.
Cr Cl >= 60 m L/min: no adjustment. Cr Cl 30-59 m L/min: reduce dose by 20%. Cr Cl < 30 m L/min: contraindicated.
Child-Pugh Class B or C: reduce dose to 975 mg/m2. No data for severe impairment.
No specific guidelines; use caution in severe hepatic impairment (Child-Pugh class C) and consider dose reduction based on tolerability.
650 mg/m2 intravenously over 1 hour daily for 5 consecutive days, repeated every 21 days.
1-21 years: 5 mg/m2 IV over 2 hours daily for 5 days every 28 days; reduce dose by 50% in patients with renal impairment.
No specific dose adjustment recommended; monitor renal function and hematologic toxicity closely.
No specific dose adjustment, but monitor renal function closely due to age-related decline and increased risk of toxicity.
Severe neurotoxicity, including Guillain-Barré-like syndrome, peripheral neuropathy, and CNS demyelination. Avoid in patients with severe pre-existing neurological conditions.
WARNING: HEMATOLOGIC TOXICITY, INFECTION, AND HEPATIC TOXICITY. Clolar suppresses bone marrow function, causing severe neutropenia, thrombocytopenia, and anemia. Fatal infections have occurred. Hepatic toxicity, including hepatic failure and death, has been reported. Monitor blood counts and liver function frequently.
Monitor for neurological toxicity; may require discontinuation.,Hematologic toxicity: neutropenia, thrombocytopenia, anemia.,Increased risk of infection.,Tumor lysis syndrome prophylaxis required.,Hepatotoxicity and renal toxicity.
Bone marrow suppression: severe neutropenia, thrombocytopenia, and anemia require close monitoring. Infections: serious and fatal infections (bacterial, fungal, viral) may occur. Hepatic toxicity: elevation of liver enzymes, bilirubin, and hepatic veno-occlusive disease. Renal toxicity: increased creatinine, hematuria, and hemolytic uremic syndrome-like reactions. Cardiac toxicity: pericardial effusion, hypotension, and ventricular dysfunction. Tumor lysis syndrome. Hypersensitivity reactions. Use in pregnancy: embryo-fetal toxicity. Vaccination: avoid live vaccines.
Hypersensitivity to nelarabine or its components.,Severe pre-existing neurological disorders (e.g., Guillain-Barré syndrome, peripheral neuropathy).,Pregnancy (may cause fetal harm).
Absolute: Hypersensitivity to clofarabine or any component of the formulation. Relative: Severe hepatic impairment (bilirubin >3 mg/d L or transaminases >5x ULN). Severe renal impairment (creatinine clearance <30 m L/min).
No known food interactions. Maintain adequate hydration to prevent tumor lysis syndrome. Avoid grapefruit juice? No evidence for interaction.
No specific food interactions are documented. However, maintain adequate hydration to reduce risk of nephrotoxicity and tumor lysis syndrome. Avoid grapefruit and grapefruit juice as they may affect metabolism via CYP3A4 (theoretical concern, though clofarabine is primarily renally excreted).
Nelarabine is embryotoxic and fetotoxic in animal studies. It is classified as FDA Pregnancy Category D. There is evidence of fetal harm in pregnant women, including increased risk of congenital malformations, intrauterine growth restriction, and fetal death. Use during the first trimester carries highest risk of major malformations; second and third trimester exposure may cause myelosuppression and low birth weight. Avoid in pregnancy unless benefit outweighs risk.
Clofarabine is contraindicated in pregnancy. Based on its mechanism of action (inhibitor of DNA synthesis) and animal studies, there is a high risk of fetal harm if administered during pregnancy. In the first trimester, there is a significant risk of embryolethality and teratogenicity (structural anomalies). In the second and third trimesters, fetal growth restriction and central nervous system damage may occur. Pregnancy must be excluded before initiation.
No human data on nelarabine excretion in breast milk. Due to its mechanism of action (DNA synthesis inhibition) and potential for serious adverse effects in the nursing infant, breastfeeding is contraindicated during therapy and for at least 3 months after the last dose.
No data available on the excretion of clofarabine into breast milk or its effects on the nursing infant. Due to potential for serious adverse reactions (e.g., myelosuppression, gastrointestinal toxicity), breastfeeding is contraindicated during therapy and for at least 3 months after the last dose. M/P ratio is unknown.
No established dose adjustments in pregnancy. Physiological changes in pregnancy (increased plasma volume, renal clearance, hepatic metabolism) may alter nelarabine pharmacokinetics, but no specific studies exist. Use standard weight-based dosing with careful monitoring for toxicity. Consider reducing dose if severe myelosuppression or neurotoxicity occurs.
There are no established dose adjustments for clofarabine during pregnancy, as use is contraindicated. Physiological changes in pregnancy (e.g., increased plasma volume, altered renal clearance) may affect pharmacokinetics, but no dosing guidelines exist. If inadvertent exposure occurs, immediate discontinuation is recommended and the pregnancy should be managed by a maternal-fetal medicine specialist.
Administer intravenously over 2 hours. Monitor for neurological toxicity including somnolence, ataxia, and seizures. Premedicate with antiemetics. Use in T-cell acute lymphoblastic leukemia/lymphoma after failure of two prior regimens. Contraindicated in severe renal impairment (Cr Cl <30 m L/min).
Clolar (clofarabine) is a purine nucleoside analog indicated for pediatric relapsed/refractory acute lymphoblastic leukemia. Key pearls: (1) Monitor for systemic inflammatory response syndrome (SIRS) and capillary leak syndrome; premedicate with corticosteroids. (2) Requires aggressive hydration and allopurinol for tumor lysis prophylaxis. (3) Dose reductions needed for renal impairment (Cr Cl < 60 m L/min). (4) Avoid live vaccines during and after treatment.
This drug can cause severe drowsiness and coordination problems; do not drive or operate machinery until you know how it affects you.,Report any unusual tiredness, muscle weakness, or tingling in hands/feet to your doctor immediately.,If you experience seizures, loss of consciousness, or confusion, seek emergency medical attention.,You will have regular blood tests to monitor your blood cell counts and kidney function.,This drug can cause serious infections; wash hands frequently and avoid crowds.,Use effective contraception during treatment and for at least 3 months after stopping.,Do not receive live vaccines during therapy without consulting your doctor.
Clolar is a chemotherapy drug used to treat a type of leukemia in children that has not responded to other treatments.,You may experience side effects like fever, nausea, vomiting, diarrhea, and skin rashes. Report any signs of infection or unusual bleeding.,Drink plenty of fluids as directed to prevent kidney problems. You may receive IV fluids before and after treatment.,Avoid vaccinations without doctor approval, as live vaccines are not safe during treatment.,This drug can cause severe reactions including organ inflammation and fluid retention; seek immediate medical help if you have difficulty breathing, rapid weight gain, or swelling.
"Roflumilast may increase the immunosuppressive activities of Nelarabine."
"The risk or severity of adverse effects can be increased when Docetaxel is combined with Nelarabine."
"Nelarabine may decrease the cardiotoxic activities of Acetyldigitoxin."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NELARABINE vs CLOLAR, answered by our medical review team.
NELARABINE is a Antineoplastic Agent that works by Nelarabine is a prodrug of ara-G, a deoxyguanosine analog. It is converted to ara-GTP, which accumulates in T-cells and inhibits DNA synthesis, leading to cell death.. CLOLAR is a Antineoplastic Agent that works by Clolar (clofarabine) is a purine nucleoside antimetabolite that inhibits DNA synthesis and RNA transcription. It is phosphorylated intracellularly to its active triphosphate form, which competes with adenosine triphosphate for incorporation into DNA, leading to chain termination and inhibition of DNA polymerase and ribonucleotide reductase, resulting in apoptosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NELARABINE and CLOLAR depend on the specific clinical indication. These are both Antineoplastic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NELARABINE is: 1500 mg/m2 intravenously over 2 hours on days 1, 3, and 5, repeated every 28 days.. The standard adult dose of CLOLAR is: 5 mg/m2 intravenously over 2 hours daily for 5 consecutive days. Repeat every 28 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NELARABINE and CLOLAR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NELARABINE is classified as Category C. Nelarabine is embryotoxic and fetotoxic in animal studies. It is classified as FDA Pregnancy Category D. There is evidence of fetal harm in pregnant women, including increased risk. CLOLAR is classified as Category C. Clofarabine is contraindicated in pregnancy. Based on its mechanism of action (inhibitor of DNA synthesis) and animal studies, there is a high risk of fetal harm if administered du. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.